Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis

[1]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[2]  A. Neugut,et al.  BRCA1 promoter methylation is associated with increased mortality among women with breast cancer , 2009, Breast Cancer Research and Treatment.

[3]  D. Morton,et al.  CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma , 2009, Clinical Cancer Research.

[4]  Yun Yen,et al.  Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer , 2009, Breast Cancer Research.

[5]  D. Notterman,et al.  CpG Island Methylator Phenotype Associates with Low-Degree Chromosomal Abnormalities in Colorectal Cancer , 2008, Clinical Cancer Research.

[6]  J. Issa.  Colon Cancer: It's CIN or CIMP , 2008, Clinical Cancer Research.

[7]  Lixin Wei,et al.  CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma , 2008, International journal of cancer.

[8]  V. Seewaldt,et al.  ESR1 Promoter Hypermethylation Does Not Predict Atypia in RPFNA nor Persistent Atypia after 12 Months Tamoxifen Chemoprevention , 2008, Cancer Epidemiology Biomarkers & Prevention.

[9]  M. Villalobos,et al.  Quantitative detection of methylated ESR1 and 14-3-3-σ gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy , 2008, Cancer biology & therapy.

[10]  S. Franco,et al.  A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[12]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Masaru Shinozaki,et al.  Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.

[14]  A. Marilyn Leitch,et al.  DNA Methylation in Benign Breast Epithelium in Relation to Age and Breast Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.

[15]  Paula Monteiro,et al.  Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions , 2008, Breast Cancer Research and Treatment.

[16]  Lajos Pusztai,et al.  Current status of prognostic profiling in breast cancer. , 2008, The oncologist.

[17]  C. Reynolds,et al.  Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy , 2008, Molecular Cancer Therapeutics.

[18]  K. Brown,et al.  The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. , 2008, Carcinogenesis.

[19]  Maurice B Loughrey,et al.  BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype , 2008, Breast Cancer Research.

[20]  P. Conte,et al.  Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). , 2008, Clinical breast cancer.

[21]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[22]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[23]  Peter A. Jones,et al.  Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. , 2007, Cancer cell.

[24]  S. Ringquist,et al.  Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. , 2007, Cancer letters.

[25]  O. Olopade,et al.  Estrogen receptor α, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers , 2007, Breast Cancer Research and Treatment.

[26]  R. Shaw,et al.  CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. , 2007, Oral oncology.

[27]  T. Nielsen,et al.  Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.

[28]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[29]  Xian-Jin Xie,et al.  Atypia and DNA Methylation in Nipple Duct Lavage in Relation to Predicted Breast Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[30]  Xin Hu,et al.  Correlation between CpG methylation profiles and hormone receptor status in breast cancers , 2007, Breast Cancer Research.

[31]  J. Lawrence,et al.  The disappearing Barr body in breast and ovarian cancers , 2007, Nature Reviews Cancer.

[32]  A. Verma,et al.  Tissue transglutaminase-mediated chemoresistance in cancer cells. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[33]  H. Rugo,et al.  The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations , 2007, Current treatment options in oncology.

[34]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[35]  K. Helzlsouer,et al.  The Reliability of Nipple Aspirate and Ductal Lavage in Women at Increased Risk for Breast Cancer—a Potential Tool for Breast Cancer Risk Assessment and Biomarker Evaluation , 2007, Cancer Epidemiology Biomarkers & Prevention.

[36]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[37]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[38]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[39]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[40]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[41]  V. Seewaldt,et al.  Hypermethylation of the Breast Cancer–Associated Gene 1 Promoter Does Not Predict Cytologic Atypia or Correlate with Surrogate End Points of Breast Cancer Risk , 2007, Cancer Epidemiology Biomarkers & Prevention.

[42]  Tae-You Kim,et al.  Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. , 2006, Cancer research.

[43]  J. Cuzick,et al.  Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. , 2006, The Lancet. Oncology.

[44]  J. Jónasson,et al.  Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer , 2006, Breast Cancer Research.

[45]  Q. Tao,et al.  Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. , 2006, Carcinogenesis.

[46]  T. Jenuwein.  The epigenetic magic of histone lysine methylation , 2006, The FEBS journal.

[47]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[48]  Zhe Zhang,et al.  Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid , 2006, Clinical Cancer Research.

[49]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[50]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[51]  P. Kauraniemi,et al.  Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.

[52]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[53]  S. Masood.  Cytomorphology as a risk predictor: experience with fine needle aspiration biopsy, nipple fluid aspiration, and ductal lavage. , 2005, Clinics in laboratory medicine.

[54]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[55]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[56]  K. Robertson.  DNA methylation and human disease , 2005, Nature Reviews Genetics.

[57]  J. Herman,et al.  Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation , 2005, Nature Genetics.

[58]  W. Schulz,et al.  Causes and consequences of DNA hypomethylation in human cancer. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[59]  A. Richardson,et al.  BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles , 2005, Breast Cancer Research and Treatment.

[60]  Victoria L. Seewaldt,et al.  Retinoic Acid Receptor-β2 Promoter Methylation in Random Periareolar Fine Needle Aspiration , 2005, Cancer Epidemiology Biomarkers & Prevention.

[61]  H. Willard,et al.  X-inactivation profile reveals extensive variability in X-linked gene expression in females , 2005, Nature.

[62]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[63]  Kazuyoshi Saito,et al.  Epigenetic status and aberrant expression of the maspin gene in human hepato-biliary tract carcinomas , 2005, Laboratory Investigation.

[64]  R. Walker,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .

[65]  Hai Hu,et al.  Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization. , 2004, Cancer genetics and cytogenetics.

[66]  Paul Cairns,et al.  Tumor Suppressor Gene Promoter Hypermethylation in Serum of Breast Cancer Patients , 2004, Clinical Cancer Research.

[67]  J. Herman,et al.  Hypermethylation in Histologically Distinct Classes of Breast Cancer , 2004, Clinical Cancer Research.

[68]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[69]  Pedram Argani,et al.  Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer , 2004, Cancer Research.

[70]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[71]  H. Stevenson,et al.  Molecular and Cellular Determinants of Estrogen Receptor α Expression , 2004, Molecular and Cellular Biology.

[72]  E. Sauter,et al.  Detection of Breast Cancer in Nipple Aspirate Fluid by CpG Island Hypermethylation , 2004, Clinical Cancer Research.

[73]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[74]  M. Widschwendter,et al.  DNA methylation in serum of breast cancer patients: an independent prognostic marker. , 2003, Cancer research.

[75]  M. Fackler,et al.  Methylation Profiling of Benign and Malignant Breast Lesions and Its Application to Cytopathology , 2003, Modern Pathology.

[76]  C. Lopes,et al.  Detection of gene promoter hypermethylation in fine needle washings from breast lesions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[79]  T. Soussi,et al.  Lack of HIN-1 Methylation Defines Specific Breast Tumor Subtypes Including Medullary Carcinoma of the Breast and BRCA1-Linked Tumors , 2003, Cancer biology & therapy.

[80]  A. Richardson,et al.  Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. , 2003, Cancer research.

[81]  J. Issa,et al.  Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer , 2003, Molecular and Cellular Biology.

[82]  J. Herman,et al.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. , 2002, Cancer research.

[83]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[84]  U. Lehmann,et al.  Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. , 2002, Cancer research.

[85]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[86]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[87]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[88]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[89]  B. Ljung,et al.  Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. , 2001, Journal of the National Cancer Institute.

[90]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[91]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[92]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[93]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[94]  K. Lunetta,et al.  HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[95]  S. Sukumar,et al.  Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.

[96]  A. Wolffe,et al.  Chromatin remodeling: why it is important in cancer , 2001, Oncogene.

[97]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[98]  R. Roylance,et al.  Multiple ways of silencing E‐cadherin gene expression in lobular carcinoma of the breast , 2001, International journal of cancer.

[99]  Christopher B Umbricht,et al.  Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR , 2001, The Lancet.

[100]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[101]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[102]  M. Widschwendter,et al.  Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. , 2000, Journal of the National Cancer Institute.

[103]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[104]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[105]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[106]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[107]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[108]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[109]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.

[110]  Adrian Bird,et al.  The essentials of DNA methylation , 1992, Cell.

[111]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[112]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[113]  C. Compton,et al.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. , 2007, Gastroenterology.

[114]  Ian O Ellis,et al.  Prognostic markers in triple‐negative breast cancer , 2007, Cancer.

[115]  Martin Widschwendter,et al.  Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. , 2006, Cancer research.

[116]  M. Ehrlich,et al.  Cancer-linked DNA hypomethylation and its relationship to hypermethylation. , 2006, Current topics in microbiology and immunology.

[117]  D. Lodygin,et al.  The role of epigenetic inactivation of 14-3-3sigma in human cancer. , 2005, Cell research.

[118]  V. Seewaldt,et al.  Retinoic Acid Receptor-B 2 Promoter Methylation in Random Periareolar Fine Needle Aspiration , 2005 .

[119]  J. Minna,et al.  Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[120]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[121]  K. Robertson,et al.  The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. , 1999, Nucleic acids research.